sorafenib has been researched along with Proteinuria in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, M; Haraguchi, M; Honda, T; Miuma, S; Miyaaki, H; Nakao, K; Sasaki, R | 1 |
| Chayahara, N; Goto, H; Hirokawa, M; Imamura, Y; Ito, Y; Kasahara, T; Kiyota, N; Minami, H; Miya, A; Miyauchi, A; Mukohara, T; Nagatani, Y; Nibu, KI; Otsuki, N; Suto, H; Toyoda, M | 1 |
| Cheng, AL; Dutcus, CE; Evans, TRJ; Finn, RS; Han, KH; Ikeda, M; Kraljevic, S; Kudo, M; Piscaglia, F; Ren, M; Sung, MW | 1 |
| Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
| Audard, V; Bahleda, R; Baumelou, A; Bouachi, K; Bourry, E; Izzedine, H; Khayat, D; Lang, P; Mangier, M; Massard, C; Ollero, M; Ory, V; Pawlak, A; Péchoux, C; Sahali, D; Sendeyo, K; Soria, JC; Zhang, SY | 1 |
| Chandran, CB; Flombaum, CD; Glezerman, IG; Salvatore, SP; Seshan, SV; Usui, J | 1 |
| Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S | 1 |
| Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D | 1 |
| Jonkers, IJAM; van Buren, M | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Keresztes, RS; Wu, S | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
| Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M | 1 |
4 review(s) available for sorafenib and Proteinuria
| Article | Year |
|---|---|
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Retrospective Studies; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2014 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
2 trial(s) available for sorafenib and Proteinuria
| Article | Year |
|---|---|
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Creatinine; Humans; Liver Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Sorafenib | 2019 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
8 other study(ies) available for sorafenib and Proteinuria
| Article | Year |
|---|---|
Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney; Liver Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Sorafenib | 2022 |
Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Topics: Aged; Antineoplastic Agents; Drug Substitution; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Radiation Tolerance; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; Binding Sites; Biomarkers; Carrier Proteins; Case-Control Studies; Cell Line; Female; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Nephrosis, Lipoid; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proteinuria; Renal Insufficiency; Sorafenib; Thrombotic Microangiopathies; Transcription Factor RelA; Transcription, Genetic; Transfection; Vascular Endothelial Growth Factors; Young Adult | 2014 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment | 2016 |
[Vascular and renal effects of anti-angiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease Progression; Glomerulonephritis, IGA; Humans; Hypertension; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Sorafenib; Transplantation, Homologous | 2009 |
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Indoles; Intestinal Perforation; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib | 2008 |